Everything drug pricing and policy, every day
And evidence that the “biosimilar void” has been exaggerated
And new AAM data shows expanding savings from generics and biosimilars
And unpacking Trump administration claims about whether anyone is seeing MFN prices
And more evidence that we’re in for a record-breaking spike in healthcare costs
And clear your schedules this afternoon for the latest White House drug pricing fun
Plus the CMS effort to bring obesity medicines to Medicare is off to a quick start, CVS and Walgreens say
